Clinical trial NCT02370550: Cyclosporine A in the TReatment of Interstitial Pneumonitis Associated With Sjogren's Syndrome
Official title: Cyclosporine A in the TReatment of Interstitial Pneumonitis Associated With Sjogren's Syndrome(CTRIPS): A Prospective, Randomized, Multicenter, Double-Blind Placebo-Controlled Trial
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE4
Conditions: Sjogren's Syndrome
Lead sponsor: Peking University People's Hospital
Sponsor class: OTHER
First posted: 2015-02-25
Enrollment: 240
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this large multicenter, randomized, double-blinded, controlled clinical study is to investigate the efficacy and safety of Cyclosporin A for primary Sjogren's syndrome associated pneumonitis(pSS-IP), which has important implications for the establishment of standardized diagnosis and treatment of pSS-IP.


Eligibility criteria: Inclusion Criteria:

* Patients meeting the 2002 or 2012 pSS criteria;
* Patients meeting the diagnostic criteria of interstitial pneumonitis(IP);
* Patients with exertional dyspnea consistent with grade 2 on the Magnitude of Task component of the Mahler Modified Dyspnea Index;
* Pulmonary function test: patients with percentages of forced vital capacity (FVC) to predicted values≥45%, percentage of diffusing capacity of carbon monoxide (DLco) to predicted values≥30%, forced expiratory volume in one second (FEV1) / FVC\> 65%;
* For patients who received oral glucocorticoid, the doses should be no more than 10 mg/d (or equivalent amount of other types of glucocorticoids);
* Patients who had not received any prior treatment with immunosuppressants (including but not limited to CYC, CsA, azathioprine(AZA), tacrolimus(FK-506), methotrexate, leflunomide, etc.) or had discontinued the therapy above for at least 3 months; for patients who received hydrochloroquine(HCQ), the doses should be stabilized for at least 3 months;
* Patients who had not received any prior treatment with biological agents, including but not limited to rituximab, infliximab, adalimumab, etanercept, etc., or had discontinued therapy for at least three months;
* For patients who had prior treatment with N-acetylcysteine, the doses of above drugs should be stabilized for at least 3 months;
* The women of reproductive age who had a negative urine pregnancy test. The women and men of reproductive age must receive effective contraceptive measures from the screening period to last administration of drugs;
* Patients who were able to read, to understand and to sign informed consent.

Exclusion Criteria: Patients who met any of the following criteria will not participate in this study.

* Patients with acute exacerbation of IP(AEIP);
* Arterial blood gas analysis showed respiratory failure;
* Patients with lung diseases other than IP:

  1. Patients with severe pulmonary hypertension who require specific treatments assessed by the rheumatology and immunology experts in various clinical centers;
  2. Patients with a history of smoking within the last 6 months or current smokers;
  3. Patients with other serious lung diseases, such as lung tumor or active pulmonary infection;
  4. Lung biopsy, alveolar lavage or high-resolution computerized tomography (HRCT) suggested serious lung diseases other than IP;
* Patients with other rheumatic autoimmune diseases, including but not limited to rheumatoid arthritis, systemic lupus erythematosus, inflammatory myopathy, systemic sclerosis, primary biliary cirrhosis, etc.;
* Patients with serious heart, liver, kidney diseases, hematologic and/ or endocrine diseases:

  1. Heart diseases: decompensated heart failure or refractory hypertension; clinically important abnormal ECG that may lead to unacceptable risks to enrolled patients at screening;
  2. Liver function: alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) ≥2 times the upper limit of normal (ULN);
  3. Renal function: renal tubular and/or interstitial diseases, renal insufficiency: serum creatinine≥2 ULN or glomerular filtration rate (eGFR) \<90 ml/min/1.73 m2;
  4. White blood cell (WBC) count \<3 ×109/L and/or hemoglobin (Hb) \<100 g/L and/or platelet (PLT) count \<80×109 /L;
  5. Other serious diseases: such as cancer, etc.;
* Patients with active infection or other diseases which will be aggravated with treatment of glucocorticoid and immunosuppressive therapy;
* Patients positive for HBsAg or hepatitis C antibody;
* Women during pregnancy or lactation, or cannot guarantee effective contraception;
* Patients who did not cooperate with treatment for mental illness or other reasons;
* Patients who had allergic constitution or were allergic to many drugs;
* Patients who were allergic or intolerant to CsA, CYC, or glucocorticoid.

Primary outcomes:
measure: The forced vital capacity (FVC)
timeFrame: the 52 weeks
Secondary outcomes:
measure: The diffusing capacity of carbon monoxide (DLco)
timeFrame: the 52 weeks
Other outcomes:
Locations:
city: Beijing
country: China
facility: Peking University People's Hospital
state: Beijing
Study officials:
affiliation: Peking University People's Hospital
name: Zhanguo Li, MD
role: PRINCIPAL_INVESTIGATOR
References: